Blueprint Medicines (BPMC) Gets a Hold from Barclays
In a report released today, Peter Lawson from Barclays maintained a Hold rating on Blueprint Medicines, with a price target of $129.00. The company’s shares closed yesterday at $128.40.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Lawson covers the Healthcare sector, focusing on stocks such as Blueprint Medicines, Nuvalent, and Exelixis. According to TipRanks, Lawson has an average return of -8.2% and a 36.49% success rate on recommended stocks.
The word on The Street in general, suggests a Hold analyst consensus rating for Blueprint Medicines with a $131.00 average price target.
BPMC market cap is currently $8.3B and has a P/E ratio of -52.17.
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of BPMC in relation to earlier this year. Last month, Percy H. Carter, the CSO of BPMC sold 2,659.00 shares for a total of $340,032.92.
Read More on BPMC:
Disclaimer & DisclosureReport an Issue
- Blueprint Medicines Holds Annual Stockholders Meeting
- Blueprint Medicines downgraded to Equal Weight from Overweight at Wells Fargo
- Blueprint Medicines announces data reinforcing sustained efficacy of AYVAKIT
- Blueprint Medicines price target raised to $129 from $88 at UBS
- Blueprint Medicines price target raised to $129 from $102 at Morgan Stanley
